Literature DB >> 8016668

Magnetic resonance relaxation times of normal tissue in the course of chemotherapy: a study in patients with bone sarcoma.

H C Holscher1, H J van der Woude, J Hermans, M A Nooy, J Doornbos, J L Bloem.   

Abstract

To study the effect of chemotherapy on normal fat, skeletal muscle, and bone marrow, T1 and T2 relaxation times were measured in 15 patients with bone sarcoma before and after each cycle of preoperative chemotherapy. A section plane containing the tumor and if possible the nonaffected extremity was imaged with combined multiecho spin echo and inversion recovery pulse sequences. T1 and T2 relaxation times were calculated in the normal-appearing tissues. Although some variation was found in the values in the individual patient and between patients, no systematic changes of relaxation times of fat, muscle, or bone marrow occurred in the course of treatment. We conclude that the chemotherapy used in bone sarcoma has no effect on relaxation times of normal fat, muscle, and bone marrow, and that therefore these tissues may serve as a reference for the signal intensity of tumor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016668     DOI: 10.1007/bf00197456

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  28 in total

1.  Musculoskeletal tumors: T1 and T2 relaxation times.

Authors:  H Pettersson; R M Slone; S Spanier; T Gillespy; J R Fitzsimmons; K N Scott
Journal:  Radiology       Date:  1988-06       Impact factor: 11.105

2.  The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas.

Authors:  H C Holscher; J L Bloem; M A Nooy; A H Taminiau; F Eulderink; J Hermans
Journal:  AJR Am J Roentgenol       Date:  1990-04       Impact factor: 3.959

3.  [Potentialities of MR tomography in monitoring the therapy of malignant bone tumors].

Authors:  M Just; P Gutjahr; H P Higer; S Störkel; J Rudigier; G Ritter; P Pfannenstiel
Journal:  Rofo       Date:  1987-10

4.  Use of MR imaging to assess results of chemotherapy for Ewing sarcoma.

Authors:  M A Lemmi; B D Fletcher; N M Marina; W Slade; D M Parham; J J Jenkins; W H Meyer
Journal:  AJR Am J Roentgenol       Date:  1990-08       Impact factor: 3.959

5.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

6.  Mechanisms of contrast in NMR imaging.

Authors:  F W Wehrli; J R MacFall; D Shutts; R Breger; R J Herfkens
Journal:  J Comput Assist Tomogr       Date:  1984-06       Impact factor: 1.826

7.  Osteogenic sarcoma: MR signal abnormalities of the brain in asymptomatic patients treated with high-dose methotrexate.

Authors:  H H Lien; V Blomlie; G Saeter; O Solheim; S D Fosså
Journal:  Radiology       Date:  1991-05       Impact factor: 11.105

8.  Osteosarcoma: MR imaging after preoperative chemotherapy.

Authors:  G Pan; A K Raymond; C H Carrasco; S Wallace; E E Kim; A Shirkhoda; N Jaffe; J A Murray; R S Benjamin
Journal:  Radiology       Date:  1990-02       Impact factor: 11.105

9.  Osteosarcoma: chemotherapy-induced changes at MR imaging.

Authors:  H C Holscher; J L Bloem; D Vanel; J Hermans; M A Nooy; A H Taminiau; M Henry-Amar
Journal:  Radiology       Date:  1992-03       Impact factor: 11.105

10.  The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli.

Authors:  M Campanacci; G Bacci; F Bertoni; P Picci; A Minutillo; C Franceschi
Journal:  Cancer       Date:  1981-10-01       Impact factor: 6.860

View more
  1 in total

1.  MRI of bone metastases: the choice of the sequence.

Authors:  Daniel Vanel
Journal:  Cancer Imaging       Date:  2004-03-23       Impact factor: 3.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.